Skip to main content

Targeting STAT3 in Cancer Immunotherapy


As a point of convergence for numerous oncogenic signaling pathways, signal transducer and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune response. STAT3 is broadly hyperactivated both in cancer and non-cancerous cells within the tumor ecosystem and plays important roles in inhibiting the expression of crucial immune activation regulators and promoting the production of immunosuppressive factors. Therefore, targeting the STAT3 signaling pathway has emerged as a promising therapeutic strategy for numerous cancers. In this review, we outline the importance of STAT3 signaling pathway in tumorigenesis and its immune regulation, and highlight the current status for the development of STAT3-targeting therapeutic approaches. We also summarize and discuss recent advances in STAT3-based combination immunotherapy in detail. These endeavors provide new insights into the translational application of STAT3 in cancer and may contribute to the promotion of more effective treatments toward malignancies.


Dysregulation of immune checkpoints is a protective mechanism used by a number of malignancies to escape from the immune surveillance allowing for cancer development [1]. This has inspired the idea of boosting the host immune response as an anti-cancer therapy. Indeed, the blockage of immune checkpoints, including programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), improves clinical outcomes in subsets of patients with cancers previously considered to be essentially untreatable [2,3,4]. In order to expand the array of treatable cancers as well as increase the number of patients that respond to the therapy, novel therapeutic targets and new molecules/strategies should be urgently identified and developed for immunotherapy appropriate for the clinical use.

The signal transducer and activator of transcription (STAT) proteins are a family of cytoplasmic transcription factors which share an overall general structure, organized into functional modular domains. The mammalian STAT family comprises STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 that mediate multiple intracellular signaling pathways [5]. Among them, STAT3 is involved in numerous biological processes including cell proliferation, survival, differentiation, and angiogenesis [6, 7]. In normal cells, transient activation of STAT3 (predominantly by phosphorylation) transmits transcriptional signals from cytokines and growth factor receptors at the plasma membrane to the nucleus [5]. In contrast, STAT3 becomes hyperactivated in the majority of human cancers and is generally associated with poor clinical prognosis [8]. Therefore, it is not surprising that STAT3 signaling pathway has long been recognized as a potential therapeutic target for cancer therapy owing to their roles in tumor formation, metastasis and drug resistance [9,10,11,12]. Moreover, accumulating evidence reveals that STAT3 hyperactivation can mediate tumor-induced immunosuppression at many levels [13, 14]. Given the similarities between tumorigenesis and STAT3-dependent immunity, new therapeutic strategies that target STAT3 signaling pathway may open up new avenues for long-lasting and multilayered tumor control.

This review outlines the role of the STAT3 pathway in tumor immunity, summarizes the recent progress in STAT3-centered anti-cancer approaches, and highlights future directions for the clinical immunotherapy.

The STAT3 signaling pathway

STAT3 is a protein consisting of 770 amino acids and characterized by the presence of 6 functionally conserved domains, including the amino-terminal domain (NH2), the coiled-coil domain (CCD), the DNA-binding domain (DBD), the linker domain, the SRC homology 2 (SH2) domain, and the carboxyl-terminal transactivation domain (TAD) (Fig. 1a). Among them, SH2 is the most highly conserved STAT domain and plays a crucial role in signaling via binding to specific phosphotyrosine motifs [15]. In an unstimulated cell, STAT3 is tightly regulated by negative modulators to maintain an inactive state in the cytoplasm. These modulators include members of the protein inhibitor of activated STAT (PIAS), suppressor of cytokine signaling (SOCS) families, protein tyrosine phosphatases (SHP1, SHP2, PTPN1, PTPN2 PTPRD, PTPRT and DUSP22), and ubiquitin enzymes [8]. In response to stimuli, STAT3 becomes activated mainly by direct phosphorylation at tyrosine (705) and serine (727) residues induced by its upstream ligands including Janus kinases (JAKs), tyrosine kinases, cytokines and several non-receptor tyrosine kinases such as SRC and ABL; the phosphorylation induces dimerization of STAT3 proteins followed by nuclear translocation, DNA binding, and eventually execution of their nuclear functions [15].

Fig. 1

The domain structure and signaling pathway of STAT3. a Schematic domain structure of STAT3. STAT3 is characterized by the presence of six different functional domains, including an amino-terminal domain (NTD) for cooperative binding of STAT proteins to multiple consensus DNA sites, a coiled-coil domain (CCD) for recruitment of STAT3 to the receptor as well as subsequent phosphorylation, dimerization and nuclear translocation, a DNA-binding domain (DBD) for recognizing and binding to a specific consensus DNA sequence, a linker domain for connecting the DBD with the SRC homology 2 (SH2) domain, a SH2 domain for recruitment and activation as well as dimerization of the STAT3 molecule by interacting with phosphorylated tyrosine residues in the opposing subunit, and a carboxyl-terminal transactivation domain (TAD). b STAT3 signaling pathway. STAT3 is activated by upstream growth factor kinases and cytokine receptors. Non-receptor tyrosine kinases such as SRC and ABL can also lead to constitutive activation of STAT3. Phosphorylated STAT3 dimerizes and translocates to nucleus, which causes the transcription of target genes including immunosuppression, angiogenesis, metastasis, proliferation and survival. The signaling pathway can be inhibited by SOCS proteins, PIAS proteins, and protein tyrosine phosphatases (PTPases), etc. c Interplay between noncoding RNAs and STAT3 signaling pathway. On the one hand, miRNAs and lncRNAs can regulate STAT3 activation through not only directly targeting STAT3, but also targeting the components of the STAT3 signaling pathway, such as IL-6, JAK2, SOCS1 and PIAS3; CircRNAs usually regulate STAT3 by acting as sponges for miRNAs. On the other hand, STAT3 is able to regulate miRNAs and lncRNAs expression in many ways.

Beyond phosphorylation, other posttranslational modifications (i.e. acetylation, methylation, and sumoylation) can also regulate STAT3 transcriptional activity through altering STAT3 phosphorylation, and thus add another layer of complexity for STAT3 hyperphosphorylation in cancers (Fig. 1b). For instance, acetylation at several lysine residues within both the NH2 and SH2 domains, primarily mediated by the CBP/p300 acetyltransferase, can enhance STAT3 transactivating potential, which is associated with increased dimer stabilization, tyrosine 705 phosphorylation, nuclear translocation, and localized histone hyperacetylation of target promoters [16]. In contrast, deacetylation by several deacetylases, such as HADC1-3, SIRT1 and Loxl3, inhibits transcription of STAT3 targets [17,18,19]. The dynamic balance of acetylation and deacetylation plays a role in STAT3 activation and is involved in various cellular events. Similarly, methylation and sumoylation are also emerging as important regulatory mechanisms for STAT3 activity. SMYD2-dependent methylation of STAT3 contributes to the hyperphosphorylation of STAT3, whereas EZH2- and SET9-dependent dimethylation of STAT3 inhibits the activity of DNA-bound STAT3 dimers [20,21,22]. Sumoylation at the lysine 451 of STAT3 by SUMO2/3 can promote its interaction to the nuclear phosphatase TC45, thereby restraining phosphorylated STAT3 in the nucleus, while de-sumoylation by SENP3 leads to the hyperphosphorylation of STAT3 [23]. However, androgen receptor degradation enhancer ASC-J9 can inhibit the STAT3 phosphorylation via inducing the sumoylation of STAT3 at lysine 679 [24].

Additionally, increasing evidence suggests that noncoding RNAs (ncRNAs) can directly or indirectly modulate STAT3 activity (Fig. 1c). As the most extensively studied ncRNAs, numerous microRNAs (miRNAs) have been shown to target STAT3 directly and certain components of STAT3 signaling pathway (IL-6, JAK2, SOCS1, PIAS3, etc.), thereby modulating STAT3 expression and activation [8, 25,26,27,28,29]. For instance, miR-125b-5p can directly target STAT3 and inhibit its expression [27], while miR-218 indirectly suppresses STAT3 activation by targeting IL-6 receptor and JAK3 [28]. More recently, it has shown that exosome-mediated transfer of certain miRNAs, such as miR-193a-3p, miR-210-3p and miR-5100, can promote metastasis of lung cancer by enhancing STAT3 activity [29], although the molecular mechanisms await further investigation. Likewise, long non-coding RNAs (lncRNAs) can modulate the expression and activation of STAT3 directly or indirectly through multiple mechanisms [30,31,32,33]. For instance, lincRNA-p21 can inhibit the STAT3 transcriptional activity via directly binding to STAT3 [30]. Lnc-BM can bind to the JH2 domain of JAK2, which increases JAK2 activation, and thus indirectly enhances activity of STAT3 [32]. FLANC, a novel primate-specific lncRNA, has shown to upregulate and prolong the half-life of phosphorylated STAT3, but not total STAT3, albeit the underlying mechanism remains unknown [34]. Intriguingly, a recent study revealed that LINC00908-encoded polypeptide ASRPS can directly bind to the CCD domain of STAT3, and thus reduce STAT3 phosphorylation [35]. In general, circular RNAs (circRNAs) can modulate gene expression by acting as sponges of endogenous miRNAs. It has shown that circ-HIPK3, circ_0076305 and circ-STAT3 positively modulate STAT3 signaling by sponging miR-124-3p, miR-296-5p, and miR-29a/b/c-3p, respectively [36,37,38]. In parallel, STAT3 has a capacity of regulating ncRNAs directly or indirectly. The regulation of miR-21 by STAT3 has been extensively studied. On the one hand, STAT3 can directly regulate miR-21 transcription in myeloma cells by binding to its upstream enhancer region [39]. On the other hand, STAT3 can upregulate miR-21 through increasing IL-6 expression [40]. The regulatory effect of STAT3 in lncRNAs is also emerging. STAT3 can directly bind to the promoter region of certain lncRNAs, such as SNHG17, DUXAP8 and HAGLROS, and thus contributes to their overexpression in cancers [41,42,43].

As described above, STAT3 activity can be influenced by many factors such as numerous post-translational modifications and multiple ncRNAs regulation. These complexities, together with the fact that the STAT3 signaling pathway is responsive to a great variety of cellular stresses and stimuli [44], pose difficulties in our understanding of abnormal hyperactivated STAT3 in cancers. Future investigations delineating the regulatory network of STAT3 will likely facilitate the clinical translation of STAT3-based therapies for human malignancy.

STAT3-driven tumor immunosuppression

The tumor microenvironment (TME) is a highly complex and heterogenous ecosystem consisting tumor-infiltrating immune cells, cancer-associated fibroblasts (CAFs), smooth muscle cells, endothelial cells, and the tumor cells [45, 46]. It is becoming increasingly evident that TME can promote the progression of cancer and mediate therapeutic resistance, particularly against cancer immunotherapy [47, 48]. Gathered evidence suggests that STAT3 becomes hyperactivated not only in cancer cells themselves but also in immune cells and CAFs within the TME [13, 49,50,51,52]. The hyperactivation of STAT3 in TME compartments might have a significant impact on anti-tumor immunity through various mechanisms (described below in more detail).

STAT3 in tumor cells

In tumor cells per se, hyperactivated STAT3 decreases the expression of immune-stimulating factors including interferons (IFNs), pro-inflammatory cytokines (IL-12, TNF-α) and chemokines (CCL5, CXCL10), while increases the expression of certain cytokines and growth factors (IL-6, IL-10, TGFβ, and VEGF), thereby exerting profound immune effects (Fig. 1b) [53]. For instance, STAT3 can suppress the secretion of type 1 IFNs (IFN-Is) and IFN-I-responsive genes via multiple actions, such as attenuating the activation of IFN-I signaling, reducing the expression of ISGF3 components, and impairing the potential of ISGF3 transactivation [54, 55].

In tumor cells, STAT3 often interacts with other signaling pathways, such as NF-κB, to confer robustness for tumor progression [44, 56, 57]. NF-κB signaling is of importance for both inflammation-induced carcinogenesis and anti-tumor immunity [57]. NF-κB (especially RELA) can upregulate a spectrum of targets involved in chronic inflammation and cancer initiation such as cyclooxygenase 2, IL-6, IL-23, and IL-1β [44]. Several layers of STAT3-NF-κB crosstalk have been identified thus far: (1) both NF-κB and STAT3 are frequently activated in the same tumor cells and TME-associated infiltrating immune cells, and share a wide range of common targets that participate in cell proliferation, metastasis, anti-apoptosis, and angiogenesis [56]; (2) STAT3 can prolong nuclear retention of RELA through p300-mediated acetylation, leading to the persistent activation of NF-κB [58]; (3) many cytokines (i.e. IL-6) can in turn simultaneously activate STAT3 and NF-κB [57]; (4) it has recently been demonstrated that NF-κB activity in pancreatic CAFs shielded cancer cells from immune attack by increasing CXCL12 expression [59]. Given the well-known feedforward loop between CXCL12 and STAT3 [60, 61], it is possible that STAT3 contributes to NF-κB-mediated immune evasion by this vicious cycle.

STAT3 in immune cells

STAT3 also plays a pivotal role in a plethora of tumor-infiltrating immune cells that predominantly comprise the TME and recent comprehensive reviews have covered this topic [62,63,64]. Here we would only like to briefly mention the diverse functions of STAT3 in immune cell milieu, together with some recent advances that throw new lights on our understanding of its extremely sophisticated regulation.

Hyperactivation of STAT3 in tumor-infiltrating immune cells causes immunosuppression by inhibiting both innate and adaptive immune responses. In brief, excessive STAT3 activity in innate immune cell subsets may impair the production of pro-inflammatory mediators such as IFNγ, dampen antigen presentation, and inhibit the tumor-killing activities of effector cells. In adaptive immune subsets, elevated STAT3 activity has the ability to inhibit the accumulation of effector T cells, thereby restraining their anti-tumor effects [62,63,64]. Interestingly, some recent studies suggest previously unknown functions of STAT3 in tumor immunity. For instance, placental growth factor (PlGF) [65] and Cxxc finger protein 1 (Cxxc1) [66] can act as key upstream regulators of STAT3 signaling, which subsequently contributes to the differentiation and function of Th17 cells. STAT3 mediates the major impact of β2 adrenergic receptor on the immunosuppressive potential of myeloid-derived suppressor cells (MDSCs) in the TME [67]. In glioblastoma-infiltrating tumor-associated macrophages, STAT3 acts as a positive regulator of aryl hydrocarbon receptor (AHR) and thus increases the recruitment of tumor-associated macrophages and tumor growth [68]. It has been shown that STAT3 modulates the abundance and function of regulatory T (Treg) cells in response to radiation therapy in head and neck cancer, suggesting that STAT3 inhibition may be beneficial for patients receiving radiation [69].


CAFs are the key component of the tumor stroma and contribute to cancer progression and treatment failure by modifying the extracellular matrix, secreting soluble factors, supporting angiogenesis and metastasis, and inhibiting anti-tumor immune responses [70]. There is a growing body of evidence to support that STAT3 can be activated in CAFs by numerous cytokines including leukemia inhibitory factor (LIF) [71]. This STAT3 hyperactivation enables CAFs to produce various immunosuppressive factors such as IL-6, TGFβ, EGF, VEGF, and CCL2, thereby contributing to the pro-oncogenic phenotype of these fibroblasts [72, 73]. Moreover, a recent study revealed that increased phosphorylation of STAT3 in CAFs is associated with reduced overall survival in colorectal cancer patients, and STAT3 activation in CAFs enhances intestinal tumor growth in vivo [74], exemplifying the importance of STAT3 activation in CAFs for cancer initiation and progression.

STAT3-mediated crosstalk between cancer cells and diverse cell subsets in the TME

Aberrantly activated STAT3 can lead to tumor-induced immunosuppression via propagating the crosstalk between cancer cells and their immunological microenvironment. In tumor cells, hyperactivated STAT3 promotes the expression of immunosuppressive factors such as VEGF, IL-6, and IL-10 [53]. Meanwhile, these tumor-derived factors that also happen to be STAT3 activators could be transited to the TME, and thus enhance STAT3 signaling in various immune cell subsets and CAFs (Fig. 2).

Fig. 2

STAT3 induces the immunosuppression in the TME. STAT3 activity in tumor cells supports multiple hallmarks of cancer, including increased secretion of immunosuppressive factors such as IL-6, IL-10 and EGFR, which can activate STAT3 in the innate and adaptive immune cell subsets as well as CAFs in the TME. Likewise, immune cells and CAFs within the TME can release certain factors including IL-6, which subsequently enhance STAT3 signaling in tumor cells. Elevated STAT3 in the TME has dual effects. On the one hand, STAT3 favors the accumulation and enrichment of immunosuppressive Treg cells and B cells, as well as the polarization of M2-like macrophages, which instigate immune evasion. Particularly, STAT3 is a major driver for increased expression of immune checkpoint molecules (such as PD-L1, PD-L2 and CTLA-4) in these cells. On the other hand, STAT3 in CD8+ T cells, NK cells and neutrophils evokes restrained anti-tumor cytolytic activities. STAT3 can also inhibit the anti-tumor ability of DCs through dampening their maturation, activation and antigen presentation. Besides, STAT3 in CAFs can promote their proliferation, survival and migration, and drive the remodeling of tumor stroma for tumor progression. Collectively, STAT3 induces the immunosuppression in the TME, thereby promoting tumor progression with diminishing the anti-tumor immunity.

In particular, STAT3 hyperactivation in tumor cells has a vital role in dendritic cells (DCs) maturation. DCs essentially are monocytes at a differentiated stage and the key antigen presenting cells of the immune system. As immune sentinels, DCs play an important role in the initiation of T-cell response against tumors, while immature DCs generally induce immune tolerance [75]. Hyperactivated STAT3 in tumor cells can suppress the expression of IL-12 and TNF-α, leading to a decrease in Bcl-2 expression in DCs [53]. STAT3 also represses the expression of major histocompatibility complex (MHC) class II complexes and co-stimulatory signals (CD80 and CD86), which are essential to the antigen presenting function of DCs [13]. Meanwhile, STAT3 inhibits DC maturation and innate immunity through negatively regulating the expression of CXCL10 and CCL5 [53]. Furthermore, the immunosuppressive factors such as IL-6, IL-10, and VEGF induced by STAT3 can inhibit DC generation through reducing protein kinase C beta II (PKCβII) expression [76]. Given that immature DCs cannot activate antigen-specific CD8+ T cells, activated STAT3 signaling in tumor cells reduces the anti-tumorigenic effector functions of CD8+ T cells.

What’s more, certain factors released by CAFs can modulate STAT3 signaling in other cell types in the tumor milieu. TGFβ, an evolutionarily conserved regulator of tumorigenesis, is a crucial driver of the activity of CAFs. Accumulating evidence suggests that TGFβ-stimulated CAFs increase the secretion of IL-6 and IL-11, which trigger GP130/STAT3 signaling in cancer cells and thus promote cancer metastasis and progression [77,78,79,80]. STAT3 is also involved in the crosstalk between CAFs and immune cells. For example, CCL2 secreted from CAFs with STAT3 hyperactivation can promote the recruitment of immunosuppressive MDSCs and hepatocarcinogenesis [72]. Moreover, the differentiation of these recruited MDSCs has been shown to be controlled in an IL-6/STAT3-dependent manner [81]. In addition, IL-6 derived from CAFs can activate STAT3 in DCs, which subsequently induce liver cancer immune escape through impairing T-cell proliferation and promoting Treg cells expansion [82]. STAT3 signaling in CAFs and other cells orchestrates stromal remodeling of the TME characterized by collagen fibrogenesis, collagen disorganization and fibroblast contractility; the remodeling of the TME is not only important for cancer cell migration and invasion, but also plays a critical role in resistance to therapeutic intervention [83, 84].

Overall, the outcome of STAT3-mediated crosstalk between cancer cells and tumor-infiltrating cells within the TME is to promote tumor growth and development, along with diminished anti-tumor immunity (Fig. 2).

Targeting STAT3 for cancer immunotherapy

Direct targeting of STAT3

Although targeting STAT3 has been extensively investigated for decades, this field still remains largely unexplored. The most common approach in targeting STAT3 directly is to prevent the formation of functional STAT3 dimers through disrupting the domains of SH2, DBD, or NTD [85, 86]. In general, direct inhibitors of STAT3 can be classified into three categories: peptides, small molecules and oligonucleotides. Studies of these inhibitors on pre-clinical cancer models are summarized in Table 1 [87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112] and relevant ongoing clinical trials are introduced in Table 2 [117,118,119].

Table 1 Studies of STAT3 inhibitors on pre-clinical cancer models
Table 2 STAT3 inhibitors in currently on-going clinical trials

Peptides are usually designed based on the structure of amino acid residues in STAT3 protein and can be directed towards different domains. Phosphopeptide inhibitor (PY*LKTK), derived from the binding peptide sequence of the STAT3-SH2 domain, represents the first successful attempt to disrupt STAT3 dimerization [89]. However, the further development of peptide for the clinical use is currently limited due to their poor cellular permeability and lack of stability in vivo, and even the second-generation peptidomimetics are largely suffering from similar limitations [127].

Non-peptide small molecules capable of disrupting phosphorylation of STAT3 or STAT3-STAT3 dimerization have recently emerged as an attractive alternative approach to the above. These small molecule inhibitors usually selectively bind to the SH2, the DBD, or the NTD domain of STAT3 to block transcription of target genes [85]. BBI608 (Napabucasin), a small molecule inhibitor that selectively binds to the DBD domain of STAT3, is the only direct STAT3 inhibitor that has advanced into phase III trials thus far. The excellent outcome of a recent phase III monotherapy trial suggested that BBI608 has potential implication in advanced colorectal cancer [117]. Moreover, FDA has approved BBI608 as an orphan drug for treatment of gastric and pancreatic cancer based on the promising results in phase I/II clinical trials.

Numerous small molecule inhibitors of STAT3 have been identified by virtual screening. Of note, although these inhibitors exhibit excellent physicochemical properties in vitro, most of them show poor clinical efficacy, which might be due to low aqueous solubility and low cell permeability [86]. Several novel approaches have recently emerged to overcome this dilemma, and show great promise to yield therapeutic agents to targeting transcription factors, including STAT3. For instance, the small-molecule proteolysis-targeting chimera (PROTAC)-based strategy has attracted a lot of attention because it can inhibit target protein function as well as counteract increased target protein expression [128]. The studies on PROTAC-mediated degradation of oncogenic proteins such as BRD4 [129], BCR-ABL [130], receptor tyrosine kinase (RTK) [131], and BCL-XL [132] have shown encouraging results, suggesting the potential clinical applicability of this ingenious approach. SD-36, a novel inhibitor identified by the PROTAC-based strategy, exhibits high selectivity for STAT3 and high cell permeability [98]. Moreover, SD-36 treatment can cause a profound and long-lasting suppression of tumor in mouse models of leukemia and lymphoma [98], suggesting that PROTAC-based strategy may be a promising and reliable avenue for searching small molecule inhibitors against STAT3. Further, the outstanding performance of SD-36 in cancer treatment suggests that the strategy of targeting STAT3 protein degradation may be superior to suppress STAT3 expression.

Oligonucleotides represent a new treatment strategy for ‘undruggable’ cancer targets such as STAT3. STAT3-binding decoy oligodeoxynucleotides, can sequester STAT3 and thus decrease its binding to cognate DNA sites within target genes [133]. Antisense oligonucleotides (ASOs) are designed to block STAT3 activity by targeting STAT3 mRNA. For example, AZD9150, a second-generation STAT3 ASO, targets the 3'-untranslated region (3'-UTR) of the STAT3 gene [134]. Preclinical testing and clinical evaluation have revealed the high efficacy and low toxicity of AZD9150 in oncotherapy [135, 136]. Although oligodeoxynucleotides inhibitors of STAT3 provide exquisite specificity and potency, their poor cell membrane penetrance, rapid degradation, and the lack of effective targeted delivery carriers, remain the major obstacles that impede their use in solid tumors. Aptamers have also emerged as useful targeted delivery agents for conventional drugs and small RNAs including siRNAs and miRNAs due to several advantages, such as small physical size, high stability and low immunogenicity [137]. Recently, STAT3 silencing by aptamer-siRNA chimera obtained excellent inhibition in the therapy of glioblastoma [138, 139], suggesting that the improved oligonucleotides might offer translational potential for the treatment of solid tumors.

Since STAT3 is a transcription factor, it is traditionally regarded as an undruggable target. Direct targeting of STAT3 has proven to be considerably challenging, owing in part to high sequence similarity with the other STAT members [86, 140]. Moreover, several issues such as high toxicity and poor bioavailability have become significant impediments to the clinical development of direct STAT3 inhibitors [86]. Interestingly, some FDA-approved compounds, such as Pyrimethamine and Celecoxib, have been identified as STAT3 inhibitors through drug-repositioning screening [141, 142]. These findings not only provide another source for searching STAT3 inhibitors, but also suggest potential applications of these drugs in cancer therapy. In addition, similar to combined therapy, certain bifunctional compounds are emerging and may represent a new generation of highly efficacious STAT3 inhibitors for cancer therapy in the future. For example, the compound 8u has dual immunotherapeutic and anticancer efficacy through simultaneously inhibiting indoleamine-2,3-dioxygenase 1 (IDO1) and STAT3 [143].

Indirect targeting of STAT3

In parallel with direct inhibitors, indirect inhibitors of STAT3 have been pursued by targeting the upstream or downstream components of the STAT3 signaling pathway, and hundreds of leading compounds have been identified [144,145,146,147,148]. Out of those, Ruxolitinib, Dasatinib and Siltuximab that target JAK, SRC/ABL, and IL-6 respectively, have been approved by FDA for cancer therapy. Indirect STAT3 inhibitors in currently on-going clinical trials are summarized in Table 2 [120,121,122,123,124]. Of note, indirect STAT3 inhibitors lack specificity for STAT3 and may cause fairly extensive kinase inhibition because the targeted molecules are often involved in intricate signaling pathways.

Intriguingly, it has recently been shown that phosphorylated STAT3 is present in exosomes from 5-fluorouracil (5-FU) resistant colorectal cancer cells, which contributes to acquired 5-FU resistance [149]. Given the importance and efficiency of exosomes in intercellular and interorgan communication [150, 151], these findings not only add another complexity to STAT3 regulation, but also pave a new way to inhibit the oncogenic function of STAT3, as well as to delivery STAT3 inhibitors via exosomes.

Integrating STAT3 in combination cancer immunotherapy

Immunotherapy is currently among the most promising approaches for cancer treatment. This therapeutic strategy, represented mainly by immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T), has obtained unprecedented results in patients with previously incurable cancers [3, 152]. However, there are some key challenges that need to be resolved urgently, including limited clinical response rates and significant autoimmune-related side effects [3, 153]. For instance, ICB has shown remarkable effectiveness in solid tumors including melanoma, non-small cell lung cancers and renal cancer, however, even in these cancers, the majority of patients still do not respond to the treatment [3]. Furthermore, certain types of cancer such as pancreatic cancer and prostate cancer show resistance to immune checkpoint inhibition therapy [3, 154]. Thus, combination therapy is considered to be a promising direction for improving outcomes for cancer treatment. Preclinical and clinical data suggest that combination cancer immunotherapies have enhanced therapeutic efficacy and reduced drug resistance compared with monotherapy [155, 156]. These encouraging data has triggered many investigations of combination strategies, and the combination of STAT3 inhibitors with other immunotherapy agents are also emerging (Fig. 3).

Fig. 3

Targeting STAT3 in combination cancer immunotherapy. a Summary of the key steps in the development of STAT3-targeting therapeutics. The first step in the development of STAT3-targeting therapeutics involves the systematic selection of STAT3 inhibitors (including direct or indirect inhibitors) and STAT3 inhibitors-based combined immunotherapy, and then elucidating the biology and effects of these candidates to cancer using tumor cell lines and patient samples. The next major challenge involves the in vivo model-based validation that these therapeutic candidates must undergo rigorous disease-specific in vivo testing using rodents and non-human primate models. Key challenges in translating STAT3 inhibitors into the clinic are low bioavailability and the lack of specific targeting of the tumor site. b Targeting STAT3 in combination cancer immunotherapy. Targeting STAT3 in combination cancer immunotherapy can not only enhance the anti-tumor effects, but also reduce drug resistance. Besides, combined STAT3 inhibitors with CAR-T cells can reduce excessive expansion of CAR-T cells and alleviate cytokine release syndrome (CRS), resulting in lower occurrence of immune-related adverse effects.

Combined blockade of STAT3 and immune checkpoint

Up-regulated expression of the immune checkpoint molecules, including CTLA-4, PD-1, and PD-L1, has been documented to facilitate tumor immune escape. A substantial amount of evidence has shown that STAT3 is able to directly or indirectly regulate these immune checkpoint molecules. As a transcription factor, STAT3 can increase expression of PD-1, PD-L1, and PD-L2 by direct binding to their promoters [157,158,159,160]. Meanwhile, STAT3 has been identified to indirectly induce expression of immune checkpoint molecules through modulating diverse signaling pathways. For example, STAT3 increased CTLA-4 expression in tumor-associated B cells in a JAK-dependent manner [161] and enhanced CTLA-4 expression in Treg cells through IL-10 [162]. In addition, STAT3 mediated HDAC6-induced PD-L1 expression in osteosarcoma cells [163]. Conversely, recent evidence also suggests a role of immune checkpoint molecules in STAT3 expression. Celada et al. reported that PD-1 upregulation in CD4+ T cells leads to an increase in STAT3 mRNA expression by undescribed mechanism, and the latter is required for IL-17 and TGFβ1 production [164]. Interestingly, an early study from the same research group showed PD-1 can attenuate TCR-dependent activation of PI3K/AKT pathway in CD4+ T cells [165]. Given PI3K/AKT as a known repressor of STAT3 transcription [166], it is likely that PD-1 indirectly enhances STAT3 expression through inhibition of PI3K. The reciprocal regulation of STAT3 and immune checkpoint molecules not only suggests an involvement of STAT3 in anti-tumor immunity, but also provides a promising strategy to improve the efficacy of current immune checkpoint inhibitors.

Combined blockade of STAT3 and immune checkpoint has shown encouraging results, whereby the addition of STAT3 inhibitors can enhance therapeutic efficacy, and reduce resistance to ICB immunotherapy in parallel. Dasatinib, an indirect STAT3 inhibitor against SRC/ABL, significantly facilitated anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma [115], while the combined blockade of IL-6 and PD-L1 remarkably inhibited the growth of pancreatic ductal adenocarcinoma and hepatocellular carcinoma (HCC) [167, 168]. The resistance to anti-PD-1 antibodies can be overcome by treatment with JAK inhibitor in mice with pancreatic orthotopic tumors [114]. Niclosamide blocked STAT3-induced PD-L1 transcription, and thus enhanced the efficacy of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer [169]. More recently, a phase III trial reported exciting results of STAT3-based combination therapy in treatment of advanced HCC. Compared to the first-line drug sorafenib, the combination of bevacizumab (a monoclonal antibody targeting VEGF) and atezolizumab (a PD-L1 inhibitor) can significantly prolong the overall survival and progression-free survival of patients with unresectable HCC, along with comparable adverse effects [125]. In addition, certain STAT3 inhibitors, such as BBI608 and AZD9150, combining with immune checkpoint inhibitors, are currently being tested in pre-clinical (Table 1) and clinical trials (Table 2) [126]. The promising early phase clinical trials encourage further clinical development of this combination strategy.

Combined STAT3 inhibitors and CAR-T

CAR-T cell therapy, a rapidly emerging and effective immunotherapeutic approach, has revolutionized anti-cancer therapies for hematologic malignancies, especially acute lymphoblastic leukemia and lymphoma [152]. Two Anti-CD19 CAR-T therapies are currently approved by FDA for the treatment of CD19-positive leukemia or lymphoma. Although the efficacy of CAR-T therapy in solid tumors has lagged far behind, a great number of CAR-T trials are ongoing and positive outcomes are increasingly being reported for multiple solid tumors, including glioblastoma, gastrointestinal, genitourinary, breast, and lung cancer [170]. For example, CAR-T cells targeting B7-H3, a transmembrane protein belonging to the B7 immune family, inhibited the growth of neuroblastoma, pancreatic and ovarian cancer in vitro and in xenograft mouse models without evident toxicity [171, 172].

The involvement of STAT3 signaling in CAR-T therapy is emerging. Transcriptomic profiling showed that anti-CD19 CAR-T cells from responsive patients with chronic lymphocytic leukemia had an increased IL-6/STAT3 signature, which promoted the expansion of CAR-T cells [173]. In line with this, a novel anti-CD19 CAR-T cells with constitutive activation of STAT3 showed increased proliferation and reduced terminal differentiation of CAR-T cells, and conferred superior anti-tumor effects [174]. Similarly, CAR-T cells expressing the ectodomain of the IL-4 receptor and the end domain of the IL-21 receptor activated the STAT3 pathway and enhanced Th17-like polarization, representing a potential clinical CAR-T therapy for solid tumors enriching IL-4 [175]. These studies suggest a beneficial effect of STAT3 activation in CAR-T cells.

As mentioned above, STAT3 hyperactivation in tumor stroma is immunosuppressive and can increase the expression of certain cytokines and growth factors. Accordingly, constitutive expression of an array of cytokines such as IL-6 and IL-10 potentially could increase the risk of serious adverse events of CAR-T therapy including cytokine release syndrome [176]. Thus, there are some attempts to combine CAR-T therapy with STAT3 inhibitors for improving the persistence and anti-tumor effects, as well as negating toxicities of CRA-T cells in vivo. For instance, the JAK2/STAT3 axis is a crucial driver of liver-associated MDSCs and inhibition of STAT3 increased the efficacy of CAR-T cells in liver cancer metastasis [177]. In addition, a clinical study is currently on-going, which tests the efficacy and administration of the anti-IL-6 therapy (tocilizumab) on anti-CD19 CAR-T cells associated cytokine release syndrome (NCT02906371).

Combined STAT3 inhibitors and STING agonists

Stimulator of interferon genes (STING) is a major adaptor protein that plays an important role in anti-viral and anti-tumor immunity [178]. When stimulated by cytosolic DNA, STING activates TANK-binding kinase 1 (TBK1), which subsequently phosphorylates interferon regulatory factor 3 (IRF3) to promote IFN expression [178]. Activated STING can propagate interferon receptor signaling in tumor-infiltrating DCs and elicit CD8+ T cells against tumor-associated antigens in vivo [179]. Therefore, STING agonists are of continuing research interest as novel adjuvants to boost cancer immunotherapy. A recent study showed that STING-activating nanoparticles (STING-NPs) can convert immunosuppressive tumors to immunogenic microenvironments and then induce anti-tumor immune responses and immunological memory in mice with melanoma [180]. In another study, Ramanjulu et al. reported that STING agonist can lead to complete and lasting regression of tumors in mice with colon tumors [179]. These encouraging results of preclinical studies point towards the potential for improving clinical outcomes of immunotherapy, and some STING agonists such as c-diAM (PS)2 and cGAMP are currently being evaluated in clinical trials (NCT03937141, NCT02986867).

Several previous studies have suggested potential interactions between STING signaling and STAT3-driven oncogenic pathways [181,182,183]. It has been observed that rapid colorectal cancer progression in STING-deficient mice is associated with STAT3 hyperactivation [181]. Further research found that STING plays a vital role in regulation of MDSC differentiation and anti-tumor immunity in nasopharyngeal carcinoma by increasing the expression of SOCS1, a classic repressor of STAT3 [182]. Besides, TBK1, which is activated by cytosolic DNA in a STING-dependent manner, can restrain activation of STAT3 through direct phosphorylation of STAT3 at serine 754 in the TAD [183].

Recent evidence indicates that the combination of STING agonists with STAT3 inhibitors can enhance tumor immunogenicity and optimize the immunotherapeutic effects [113, 116]. For example, combined STAT3 direct inhibitor HJC0152 with STING agonist c-diAM (PS)2 increased CD8+ T cells, reduced Treg cells and MDSCs in the TME, and thus effectively enhanced anti-tumor immunity in mice with breast cancer [113]. A preclinical study demonstrated the combination of STING agonist (cGAMP or RR-CDA) with the indirect STAT3 inhibitor VEGFR2 was maximally effective for immunotherapy-resistant tumors in breast and lung cancer [116].

STAT3 blockade can also markedly improve other effective immunotherapeutic approaches including cancer vaccines and immunostimulatory Toll-like receptor (TLR) agonists (such as CpG oligodeoxynucleotides). For example, a novel strategy combining STAT3 ASO with TLR9 stimulation (CpG oligonucleotide) has been shown to enhance the anti-tumor immunity and overcome tumor immune tolerance in prostate cancer [184]. The combination of STAT3 inhibitor and DC-based vaccine led to improved therapeutic outcomes in mouse colon cancer [185]. The beneficial outcomes of these immunotherapy combinations about STAT3 inhibitors warrant further clinical validation. Notably, STAT3 antagonists, either direct or indirect STAT3 inhibitors, are generally less likely to completely block STAT3 signaling and might not trigger severe autoimmune disorders. However, it cannot be ignored that the use of STAT3 inhibitors and other immunotherapy agents in combination may result in more frequent and severe immune-related adverse events (irAEs) compared to monotherapy. Accordingly, risk evaluations for irAEs should be part of the decision criteria for determining immunotherapy combinations. Likewise, early recognition and adequate management for irAEs are indispensable to minimize treatment-related serious complications.

Conclusions and perspectives

STAT3 becomes excessively activated in multiple human cancers, and acts as a crucial signaling node for tumor cells and TME comprising cells, especially tumor-infiltrating immune cells. Therefore, targeting STAT3 is expected to offer multiple benefits, including reduced tumor cell intrinsic proliferation, enhanced anti-tumor effects of tumor-infiltrating immune cells, and improved the immunosuppressive crosstalk within the TME. These effects have positioned STAT3 as an arisen potential promising target for cancer therapy.

To date, many endeavors have been made to target STAT3 for the development and application of new drugs. These approaches are devised to inhibit STAT3 directly by peptides, small molecules and decoy oligonucleotides, or indirectly by blocking upstream signaling pathways such as IL-6 and JAK2 pathways. Currently, the core idea of direct targeting STAT3 is to prevent the formation of functional STAT3 dimers through disrupting phosphorylation of STAT3. Beyond phosphorylation, other posttranslational modifications, such as acetylation, methylation and sumoylation, are emerging to modulate STAT3 activation through diverse mechanisms, providing a broadened list of candidate regulatory targets for the STAT3 inhibitors.

To improve the response rate and the number of responding cancer types, combined immunotherapies are now being undertaken. Combination therapies of STAT3 inhibitors with currently therapeutic anti-tumor drugs including the immune-checkpoint inhibitors may open up new possibilities for long-lasting and multilayered tumor control. Although preclinical studies and early clinical trials on combined blockade of STAT3 and immune checkpoint have shown encouraging results, their clinical outcomes await further investigation. Moreover, predictive biomarkers are urgently required to rationally incorporate STAT3 inhibitors into the combination immunotherapy. The ncRNAs, particularly miRNAs, might prove to be potentially promising predictive biomarkers that can provide a basis for improved precision medicine, though the related studies are currently not explored in depth.

In summary, therapeutically targeting mediators of the STAT3 signaling, which has already been shown to be beneficial in the restoration of anti-tumor immunity, provides attractive avenues that are currently being explored for the immunotherapy of cancers both as monotherapy and in combination therapies.

Availability of data and materials

Not applicable.



Aryl hydrocarbon receptor


Acute lymphoblastic leukemia




Antisense oligonucleotides


Breast cancer


B-cell lymphoma-2


Bromodomain-containing protein 4


Cancer-associated fibroblasts


Chimeric antigen receptor T cells


Coiled-coil domain


C-C motif ligand


Cluster of differentiation 80/86


Circular RNAs


Chronic lymphocytic leukemia


Chronic myelogenous leukemia


Cytokine release syndrome


Cytotoxic T-lymphocyte-associated protein 4


C-X-C motif chemokine ligand


Cxxc finger protein 1


DNA-binding domain


Dendritic cells


Dextran sodium sulfate


Dual specificity phosphatase 22


Epidermal growth factor


Epidermal growth factor receptor


Enhancer of zeste homolog 2


Fibroblast growth factor receptor


Gastric adenocarcinoma


Gastric cancer


Gastrointestinal stromal tumor


Glycoprotein 130


Histone deacetylase


Hepatocellular carcinoma


Hypoxia-inducible factor 1α


Head and neck squamous cell carcinoma


Hairpin decoy oligodeoxynucleotide


Immune checkpoint blockade


Indoleamine-2,3-dioxygenase 1




Type I interferons




Lysyl oxidase-like 3


Immune-related adverse events


Interferon regulatory factor 3


Interferon-stimulated gene factor 3


Janus kinases


Lewis lung carcinoma


Long non-coding RNAs


Leukemia inhibitory factor


Myeloid-derived suppressor cells

MHC class II:

Major histocompatibility complex class II


Matrix metalloproteinases


Somatic mutations at codon 515 of the thrombopoietin receptor


Non-coding RNAs


Amino-terminal domain


Non-small cell lung cancer


Nuclear factor-κB


N-terminal domain


Pancreatic cancer


Prostate cancer


Programmed cell death protein 1


Platelet-derived growth factor receptor


Programmed cell death 1 ligand 1


Protein kinase C β II


Primary myelofibrosis


Protein inhibitor of activated STAT


Placenta growth factor


Phosphatidylinositol 3 kinase

Post-ET MF:

Post-essential thrombocythemia myelofibrosis


Post-polycythemia vera


Proteolysis-targeting chimera


Protein tyrosine phosphatases


Protein tyrosine phosphatase non-receptor type 1


Protein tyrosine phosphatase receptor type D


Protein tyrosine phosphatase receptor type T


Receptor tyrosine kinase


Src homology 2 domain


Src homology 2 domain containing protein tyrosine phosphatase


Sirtuin 1


SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) and MYND (Myeloid-Nervy-DEAF1) domain containing 2


Suppressor of cytokine signaling


Signal transducer and activator of transcription


Stimulator of interferon genes


STING-activating nanoparticles


Small ubiquitin-like modifier 2/3


Transactivation domain


TANK-binding kinase 1


T cell receptor


Transforming growth factor β


T helper 1


Toll-like receptor


Tumor microenvironment


Tumor necrosis factor α


Regulatory T-cell


Vascular endothelial growth factor


Vascular endothelial growth factor receptor


3ʹ-untranslated region




  1. 1.

    Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current Perspectives in Cancer Immunotherapy. Cancers (Basel). 2019;11.

  2. 2.

    Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–21.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Hanlon MM, Rakovich T, Cunningham CC, Ansboro S, Veale DJ, Fearon U, et al. STAT3 Mediates the Differential Effects of Oncostatin M and TNFalpha on RA Synovial Fibroblast and Endothelial Cell Function. Front Immunol. 2019;10:2056.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281–3.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–48.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Ishibashi K, Koguchi T, Matsuoka K, Onagi A, Tanji R, Takinami-Honda R, et al. Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J Med Sci. 2018;64:103–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24:1024–35.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, et al. JAK/STAT3-Regulated Fatty Acid beta-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab. 2018;27:136–50 e5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314–21.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  14. 14.

    Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18:374–84.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  15. 15.

    Sgrignani J, Garofalo M, Matkovic M, Merulla J, Catapano CV, Cavalli A. Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development. Int J Mol Sci. 2018;19.

  16. 16.

    Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-{kappa} B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A. 2006;103:7264–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Gambi G, Di Simone E, Basso V, Ricci L, Wang R, Verma A, et al. The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3. Cancer Res. 2019;79:3076–87.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol. 2009;11:492–500.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Ma L, Huang C, Wang XJ, Xin DE, Wang LS, Zou QC, et al. Lysyl Oxidase 3 Is a Dual-Specificity Enzyme Involved in STAT3 Deacetylation and Deacetylimination Modulation. Mol Cell. 2017;65:296–309.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A. 2010;107:21499–504.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Li LX, Fan LX, Zhou JX, Grantham JJ, Calvet JP, Sage J, et al. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. J Clin Invest. 2017;127:2751–64.

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Zhou Z, Wang M, Li J, Xiao M, Chin YE, Cheng J, et al. SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer. Oncogene. 2016;35:5826–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, et al. ASC-J9((R)) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Lett. 2018;425:21–30.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Zhang L, Li J, Wang Q, Meng G, Lv X, Zhou H, et al. The relationship between microRNAs and the STAT3-related signaling pathway in cancer. Tumour Biol. 2017;39:1010428317719869.

    PubMed  Google Scholar 

  26. 26.

    Huan L, Liang LH, He XH. Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med. 2016;13:407–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Guo R, Wu Z, Wang J, Li Q, Shen S, Wang W, et al. Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. Adv Sci (Weinh). 2019;6:1801885.

    Article  CAS  Google Scholar 

  28. 28.

    Yang Y, Ding L, Hu Q, Xia J, Sun J, Wang X, et al. MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. Mol Cancer. 2017;16:141.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  29. 29.

    Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18:40.

    PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Mol Cancer. 2019;18:38.

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Luo Z, Cao P. Long noncoding RNA PVT1 promotes hepatoblastoma cell proliferation through activating STAT3. Cancer Manag Res. 2019;11:8517–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127:4498–515.

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Liang C, Zhao T, Li H, He F, Zhao X, Zhang Y, et al. Long Non-coding RNA ITIH4-AS1 Accelerates the Proliferation and Metastasis of Colorectal Cancer by Activating JAK/STAT3 Signaling. Mol Ther Nucleic Acids. 2019;18:183–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Pichler M, Rodriguez-Aguayo C, Nam SY, Dragomir MP, Bayraktar R, Anfossi S, et al. Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut. 2020.

  35. 35.

    Wang Y, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis. J Exp Med. 2020;217.

  36. 36.

    Hu D, Zhang Y. Circular RNA HIPK3 promotes glioma progression by binding to miR-124-3p. Gene. 2019;690:81–9.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Dong Y, Xu T, Zhong S, Wang B, Zhang H, Wang X, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239:116984.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Liu Y, Song J, Liu Y, Zhou Z, Wang X. Transcription activation of circ-STAT3 induced by Gli2 promotes the progression of hepatoblastoma via acting as a sponge for miR-29a/b/c-3p to upregulate STAT3/Gli2. J Exp Clin Cancer Res. 2020;39:101.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39:493–506.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110:1330–3.

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Gao H, Liu R, Sun X. STAT3-induced upregulation of lncRNA SNHG17 predicts a poor prognosis of melanoma and promotes cell proliferation and metastasis through regulating PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2019;23:8000–10.

    CAS  PubMed  Google Scholar 

  42. 42.

    Du C, Wang HX, Chen P, Chen CH. STAT3-induced upregulation of lncRNA DUXAP8 functions as ceRNA for miR-577 to promote the migration and invasion in colorectal cancer through the regulation of RAB14. Eur Rev Med Pharmacol Sci. 2019;23:6105–18.

    CAS  PubMed  Google Scholar 

  43. 43.

    Chen JF, Wu P, Xia R, Yang J, Huo XY, Gu DY, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17:6.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. 44.

    Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Bohm S, et al. Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov. 2018;8:304–19.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell. 2018;174:1293–308 e36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020.

  48. 48.

    Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. Adv Mater. 2019;31:e1803322.

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010;70:7455–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Iwata-Kajihara T, Sumimoto H, Kawamura N, Ueda R, Takahashi T, Mizuguchi H, et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol. 2011;187:27–36.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity. 2011;35:806–18.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014;124:2370–9.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Icardi L, Lievens S, Mori R, Piessevaux J, De Cauwer L, De Bosscher K, et al. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J. 2012;26:240–9.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Tsai MH, Lee CK. STAT3 Cooperates With Phospholipid Scramblase 2 to Suppress Type I Interferon Response. Front Immunol. 2018;9:1886.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  56. 56.

    Fan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4:176–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309–24.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15:283–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Garg B, Giri B, Modi S, Sethi V, Castro I, Umland O, et al. NFkappaB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. Gastroenterology. 2018;155:880–91 e8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Saha A, Ahn S, Blando J, Su F, Kolonin MG, DiGiovanni J. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice. Cancer Res. 2017;77:5158–68.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, et al. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2017;8:1773.

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Rebe C, Ghiringhelli F. STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers (Basel). 2019;11.

  63. 63.

    Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer. 2019;19:82–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Yoo SA, Kim M, Kang MC, Kong JS, Kim KM, Lee S, et al. Placental growth factor regulates the generation of TH17 cells to link angiogenesis with autoimmunity. Nat Immunol. 2019;20:1348–59.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Lin F, Meng X, Guo Y, Cao W, Liu W, Xia Q, et al. Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1. Sci Adv. 2019;5:eaax1608.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Mohammadpour H, MacDonald CR, Qiao G, Chen M, Dong B, Hylander BL, et al. beta2 Adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J Clin Invest. 2019.

  68. 68.

    Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22:729–40.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, et al. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019.

  70. 70.

    Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015;6:10204.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res. 2016;76:4124–35.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Li X, Xu Q, Wu Y, Li J, Tang D, Han L, et al. A CCL2/ROS autoregulation loop is critical for cancer-associated fibroblasts-enhanced tumor growth of oral squamous cell carcinoma. Carcinogenesis. 2014;35:1362–70.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    Heichler C, Scheibe K, Schmied A, Geppert CI, Schmid B, Wirtz S, et al. STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut. 2019.

  75. 75.

    Giovanelli P, Sandoval TA, Cubillos-Ruiz JR. Dendritic Cell Metabolism and Function in Tumors. Trends Immunol. 2019;40:699–718.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, et al. Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCbetaII abundance. Sci Signal. 2014;7:ra16.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  77. 77.

    Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  79. 79.

    Huang H, Zhang Y, Gallegos V, Sorrelle N, Zaid MM, Toombs J, et al. Targeting TGFbetaR2-mutant tumors exposes vulnerabilities to stromal TGFbeta blockade in pancreatic cancer. EMBO Mol Med. 2019:e10515.

  80. 80.

    Ham IH, Oh HJ, Jin H, Bae CA, Jeon SM, Choi KS, et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18:68.

    PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Lin Q, Ren L, Jian M, Xu P, Li J, Zheng P, et al. The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1-STAT3 signaling pathway. Cell Death Dis. 2019;10:693.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  82. 82.

    Cheng JT, Deng YN, Yi HM, Wang GY, Fu BS, Chen WJ, et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis. 2016;5:e198.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, et al. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Gastroenterology. 2015;149:1932–43 e9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  84. 84.

    Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell. 2011;20:229–45.

    CAS  PubMed  Article  Google Scholar 

  85. 85.

    Gelain A, Mori M, Meneghetti F, Villa S. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents. Curr Med Chem. 2019;26:5165–206.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Beebe JD, Liu JY, Zhang JT. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol Ther. 2018;191:74–91.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res. 2004;2:170–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Miccoli A, Dhiani BA, Mehellou Y. Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs. Medchemcomm. 2019;10:200–8.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276:45443–55.

    CAS  PubMed  Article  Google Scholar 

  90. 90.

    Ji P, Xu X, Ma S, Fan J, Zhou Q, Mao X, et al. Novel 2-Carbonylbenzo [b] thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway. ACS Med Chem Lett. 2015;6:1010–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. 91.

    Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010;70:2445–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. 92.

    Li Z, Zhu T, Xu Y, Wu C, Chen J, Ren Y, et al. A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. Am J Cancer Res. 2019;9:699–713.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. 93.

    Liu Z, Wang H, Guan L, Lai C, Yu W, Lai M. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo. Br J Pharmacol. 2020;177:298–313.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  94. 94.

    Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer. 2009;100:106–12.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Zuo M, Li C, Lin J, Javle M. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget. 2015;6:10940–9.

    PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Wang H, Liu Z, Guan L, Li J, Chen S, Yu W, et al. LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis. Pharmacol Res. 2020;153:104661.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Kim LH, Khadka S, Shin JA, Jung JY, Ryu MH, Yu HJ, et al. Nitidine chloride acts as an apoptosis inducer in human oral cancer cells and a nude mouse xenograft model via inhibition of STAT3. Oncotarget. 2017;8:91306–15.

    PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019;36:498–511 e17.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  99. 99.

    Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13:1235–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  100. 100.

    Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, et al. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunol Lett. 2017;190:20–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  101. 101.

    Soleimani AH, Garg SM, Paiva IM, Vakili MR, Alshareef A, Huang YH, et al. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma. Drug Deliv Transl Res. 2017;7:571–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  102. 102.

    Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007;104:7391–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther. 2004;3:1533–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. 104.

    Buettner R, Corzano R, Rashid R, Lin J, Senthil M, Hedvat M, et al. Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. ACS Chem Biol. 2011;6:432–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  105. 105.

    Escobar Z, Bjartell A, Canesin G, Evans-Axelsson S, Sterner O, Hellsten R, et al. Preclinical Characterization of 3beta-(N-Acetyl l-cysteine methyl ester)-2abeta,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer. J Med Chem. 2016;59:4551–62.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  106. 106.

    Son DJ, Zheng J, Jung YY, Hwang CJ, Lee HP, Woo JR, et al. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain. Theranostics. 2017;7:4632–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  107. 107.

    Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016;35:783–92.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  108. 108.

    Souissi I, Ladam P, Cognet JA, Le Coquil S, Varin-Blank N, Baran-Marszak F, et al. A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol Cancer. 2012;11:12.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  109. 109.

    Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010;115:2919–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  110. 110.

    Lo MC, Peterson LF, Yan M, Cong X, Hickman JH, Dekelver RC, et al. JAK inhibitors suppress t(8;21) fusion protein-induced leukemia. Leukemia. 2013;27:2272–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Lu X, Zhang T, Zhu SJ, Xun Q, Tong L, Hu X, et al. Discovery of JND3229 as a New EGFR(C797S) Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018;9:1123–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    Holmstrom TH, Moilanen AM, Ikonen T, Bjorkman ML, Linnanen T, Wohlfahrt G, et al. ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity. Mol Cancer Ther. 2019;18:28–38.

    CAS  PubMed  Article  Google Scholar 

  113. 113.

    Pei J, Zhang Y, Luo Q, Zheng W, Li W, Zeng X, et al. STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity. Cancer Lett. 2019;450:110–22.

    CAS  PubMed  Article  Google Scholar 

  114. 114.

    Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. 2017;6:e1291106.

    PubMed  PubMed Central  Article  Google Scholar 

  115. 115.

    Yu GT, Mao L, Wu L, Deng WW, Bu LL, Liu JF, et al. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018;75:4223–34.

    CAS  PubMed  Article  Google Scholar 

  116. 116.

    Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019;130:4350–64.

    Article  Google Scholar 

  117. 117.

    Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:263–70.

    PubMed  Article  Google Scholar 

  118. 118.

    Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6:119.

    PubMed  PubMed Central  Article  Google Scholar 

  119. 119.

    Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2:694–705.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  120. 120.

    Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, et al. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017;102:94–102.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, et al. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leuk Res. 2018;71:82–8.

    CAS  PubMed  Article  Google Scholar 

  122. 122.

    Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018;4:652–9.

    PubMed  Article  Google Scholar 

  123. 123.

    Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, et al. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018;97:1357–67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71:883–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905.

    CAS  PubMed  Article  Google Scholar 

  126. 126.

    D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, et al. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017;23:2972–80.

    CAS  PubMed  Article  Google Scholar 

  127. 127.

    Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004;3:261–9.

    CAS  PubMed  Google Scholar 

  128. 128.

    Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16:101–14.

    CAS  PubMed  Article  Google Scholar 

  129. 129.

    Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376–81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  130. 130.

    Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Eng. 2016;55:807–10.

    CAS  Article  Google Scholar 

  131. 131.

    Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, et al. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chem Biol. 2018;25:67–77 e3.

    CAS  PubMed  Article  Google Scholar 

  132. 132.

    Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  133. 133.

    Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018;17:1917–26.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  134. 134.

    Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7:314ra185.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  135. 135.

    Odate S, Veschi V, Yan S, Lam N, Woessner R, Thiele CJ. Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity. Clin Cancer Res. 2017;23:1771–84.

    CAS  PubMed  Article  Google Scholar 

  136. 136.

    Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018;128:5479–88.

    PubMed  PubMed Central  Article  Google Scholar 

  137. 137.

    Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16:181–202.

    CAS  PubMed  Article  Google Scholar 

  138. 138.

    Esposito CL, Nuzzo S, Catuogno S, Romano S, de Nigris F, de Franciscis V. STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. Mol Ther Nucleic Acids. 2018;10:398–411.

    CAS  PubMed  Article  Google Scholar 

  139. 139.

    Yoon S, Wu X, Armstrong B, Habib N, Rossi JJ. An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRalpha Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids. 2019;14:131–41.

    CAS  PubMed  Article  Google Scholar 

  140. 140.

    Heppler LN, Frank DA. Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. Trends Cancer. 2017;3:816–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  141. 141.

    Khan MW, Saadalla A, Ewida AH, Al-Katranji K, Al-Saoudi G, Giaccone ZT, et al. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol Immunother. 2018;67:13–23.

    CAS  PubMed  Article  Google Scholar 

  142. 142.

    Li H, Liu A, Zhao Z, Xu Y, Lin J, Jou D, et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J Med Chem. 2011;54:5592–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  143. 143.

    Huang R, Jing X, Huang X, Pan Y, Fang Y, Liang G, et al. Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3. J Med Chem. 2020.

  144. 144.

    Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35:939–51.

    CAS  PubMed  Article  Google Scholar 

  145. 145.

    Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50:1007–23.

    CAS  PubMed  Article  Google Scholar 

  146. 146.

    Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011;71:3972–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  147. 147.

    Tian Y, Nam S, Liu L, Yakushijin F, Yakushijin K, Buettner R, et al. Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. PLoS One. 2012;7:e49306.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  148. 148.

    Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 2015;14:100.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  149. 149.

    Zhang Q, Liu RX, Chan KW, Hu J, Zhang J, Wei L, et al. Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells. J Exp Clin Cancer Res. 2019;38:320.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  150. 150.

    Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367.

  151. 151.

    Xu H, Du X, Xu J, Zhang Y, Tian Y, Liu G, et al. Pancreatic beta cell microRNA-26a alleviates type 2 diabetes by improving peripheral insulin sensitivity and preserving beta cell function. PLoS Biol. 2020;18:e3000603.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  152. 152.

    June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

    CAS  PubMed  Article  Google Scholar 

  153. 153.

    Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020.

  154. 154.

    O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019.

  155. 155.

    Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, et al. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity. 2020;52:357–73 e9.

    CAS  PubMed  Article  Google Scholar 

  156. 156.

    Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020–31.

    CAS  PubMed  Article  Google Scholar 

  157. 157.

    Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633–7.

    CAS  PubMed  Article  Google Scholar 

  158. 158.

    Song TL, Nairismagi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132:1146–58.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  159. 159.

    Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017;19:1189–201.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  160. 160.

    Yoyen-Ermis D, Tunali G, Tavukcuoglu E, Horzum U, Ozkazanc D, Sutlu T, et al. Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS. Sci Rep. 2019;9:11697.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  161. 161.

    Herrmann A, Lahtz C, Nagao T, Song JY, Chan WC, Lee H, et al. CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res. 2017;77:5118–28.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  162. 162.

    Hsu P, Santner-Nanan B, Hu M, Skarratt K, Lee CH, Stormon M, et al. IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1. J Immunol. 2015;195:3665–74.

    CAS  PubMed  Article  Google Scholar 

  163. 163.

    Keremu A, Aimaiti A, Liang Z, Zou X. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother Pharmacol. 2019;83:255–64.

    CAS  PubMed  Article  Google Scholar 

  164. 164.

    Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, et al. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production. Sci Transl Med. 2018;10.

  165. 165.

    Celada LJ, Rotsinger JE, Young A, Shaginurova G, Shelton D, Hawkins C, et al. Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4(+) T Cell Proliferation. Am J Respir Cell Mol Biol. 2017;56:74–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  166. 166.

    Krasilnikov M, Ivanov VN, Dong J, Ronai Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene. 2003;22:4092–101.

    CAS  PubMed  Article  Google Scholar 

  167. 167.

    Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67:320–32.

    CAS  PubMed  Article  Google Scholar 

  168. 168.

    Liu H, Shen J, Lu K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Biochem Biophys Res Commun. 2017;486:239–44.

    CAS  PubMed  Article  Google Scholar 

  169. 169.

    Luo F, Luo M, Rong QX, Zhang H, Chen Z, Wang F, et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J Immunother Cancer. 2019;7:245.

    PubMed  PubMed Central  Article  Google Scholar 

  170. 170.

    Bagley SJ, O'Rourke DM. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. Pharmacol Ther. 2019;107419.

  171. 171.

    Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 2019;35:221–37 e8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  172. 172.

    Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res. 2019;25:2560–74.

    CAS  PubMed  Article  Google Scholar 

  173. 173.

    Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  174. 174.

    Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24:352–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  175. 175.

    Wang Y, Jiang H, Luo H, Sun Y, Shi B, Sun R, et al. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment. Front Immunol. 2019;10:1691.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  176. 176.

    Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–85.

    CAS  PubMed  Google Scholar 

  177. 177.

    Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, et al. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene. 2019;38:533–48.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  178. 178.

    Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126:2404–11.

    PubMed  PubMed Central  Article  Google Scholar 

  179. 179.

    Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439–43.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  180. 180.

    Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14:269–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  181. 181.

    Zhu Q, Man SM, Gurung P, Liu Z, Vogel P, Lamkanfi M, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol. 2014;193:4779–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  182. 182.

    Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 2019;26:2314–28.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  183. 183.

    Hsia HC, Hutti JE, Baldwin AS. Cytosolic DNA Promotes Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation by TANK-binding Kinase 1 (TBK1) to Restrain STAT3 Activity. J Biol Chem. 2017;292:5405–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  184. 184.

    Moreira D, Adamus T, Zhao X, Su YL, Zhang Z, White SV, et al. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res. 2018;24:5948–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  185. 185.

    Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references




This work was supported by the Ministry of Science and Technology of China (2018ZX09201018-005), the National Natural Science Foundation of China (81970561, 81502631, 81570527, 91540113), the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18049), and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Z20191005, Z20201003).

Author information




Y.T. and X.F. conceived the idea; S.Z., Q.T. and B.L. performed the literature search and draft the manuscript; W.H. revised and edited the manuscript; X.F. and Y.T. supervised and revised the manuscript. The author(s) read and approved the final manuscript.

Corresponding authors

Correspondence to Yan Tian or Xianghui Fu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All the authors have approved the final manuscript for publication.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zou, S., Tong, Q., Liu, B. et al. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer 19, 145 (2020).

Download citation


  • STAT3
  • Cancer
  • Immunosuppression
  • Immunotherapy
  • Immune checkpoint blockade
  • CAR-T